Regeneron Reports Third Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Pharma (REGN) PT Raised to $440 at SunTrust Robinson Humphrey
November 9, 2017 3:47 PM ESTSunTrust Robinson Humphrey analyst Suneja Yatin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $435.00) while maintaining a Hold rating following Q3 results highlighted by Eylea U.S. sales (+3.7% Q/Q), above (+2.1%) consensus.
The firm views near-term catalysts (Dupi in Asthma, anti-PD-1 in CSCC) as already priced-in.
... MoreRegeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... More